187P Phase I/II study of the oral CCR4 antagonist, FLX475, as monotherapy and in combination with pembrolizumab in advanced cancer. (December 2022) - Lin, C-C.; Kim, T.M.; Desai, P.; Lee, K.H.; Feng, Y-H.; Ngamphaiboon, N.; Kim, S-B.; Yang, M-H.; Muzaffar, J.; Chmielowski, B.; Swiecicki, P.L.; Bowyer, S.E.; et al.